<DOC>
	<DOCNO>NCT01204034</DOCNO>
	<brief_summary>The objective study evaluate effect combination formoterol beclometasone dipropionate central peripheral airway dimension COPD patient use Computational Fluid Dynamics ( CFD ) . Further , effect combination therapy lung function ( spirometry , body plethysmography ) , BODE index , COPD assessment test ( CAT ) Borg CR10 scale assess safety evaluate .</brief_summary>
	<brief_title>Study Assess Effect Formoterol Beclomethasone Dipropionate Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Patients document COPD base follow criterion : Smoking history least 10 packyears Decreased Tiffeneau index : FEV1/FVC &lt; 0.70 Male female patient age â‰¥ 40 year Patients treat accord 'Global initiative chronic Obstructive Lung Disease ' ( GOLD ) guideline Patients present Moderate COPD FEV1 50 80 % predict GOLD 2 ) Severe COPD FEV1 30 50 % predict ( GOLD 3 ) Very severe COPD FEV1 low 30 % predict ( GOLD 4 ) Patients maintain stable respiratory medication 6 week prior screen Patients cooperative attitude ability train correctly use pMDI Written inform consent obtain Pregnant lactate female female risk pregnancy Unstable patient develop exacerbation last 4 week Inability carry pulmonary function test Diagnosis asthma define current 'Global Initiative Asthma ' ( GINA ) guideline Patients uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study Patients QTc interval ( Bazett 's formula ) screen visit electrocardiogram ( ECG ) test &gt; 450 msec Cancer chronic disease poor prognosis /or affect patient status History alcohol drug abuse Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient Patients unlikely comply protocol unable understand nature , scope possible consequence study Patients receive investigational new drug within last 4 week prior screen visit Patients treat nonpermitted concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Beclomethasone Dipropionate</keyword>
	<keyword>Computational Fluid Dynamics</keyword>
	<keyword>Functional Imaging</keyword>
	<keyword>Central Peripheral Airways</keyword>
	<keyword>BODE index</keyword>
	<keyword>COPD Assessment Test ( CAT )</keyword>
	<keyword>Borg CR10 scale</keyword>
</DOC>